慢性心力衰竭的天然尿素测试和生存预测模型:增加预后价值的系统审查
Charlotte A Smith1, Kathryn S Taylor2, Nicholas R Jones2
1Royal Devon University Healthcare NHS Foundation Trust, Royal Devon and Exeter Hospital, Exeter, UK.
Diagnostic and prognostic research
|December 9, 2025
概括
B型尿素 (BNP) 和N终端proBNP (NT-proBNP) 改善了慢性心力衰竭 (CHF) 的死亡率预测. 然而,需要研究一致性才能充分理解它们的附加预后价值.
科学领域:
- 心脏病学 心脏病学
- 生物标志物 生物标志物
- 预测模型的预测建模
背景情况:
- 高尿素水平表明慢性心力衰竭 (CHF) 的结果不佳.
- 在CHF预后模型中,B型尿素 (BNP) 和N终端proBNP (NT-proBNP) 的增加的预测准确性需要进一步澄清.
研究的目的:
- 系统地审查和分析关于BNP和NT-proBNP在预测CHF成人患者死亡率的附加值的研究.
- 评估这些生物标志物对多变量预后模型性能的影响.
主要方法:
- 1990年1月至2024年2月期间发表的14项研究 (50,949名参与者) 的系统综述和叙事分析.
- 包括的研究集中在CHF的预后模型开发/验证上;排除的研究具有关于晚期HF,并发症或膜HF的特定标准.
- 使用歧视,校准,c统计差异,净重新分类指数 (NRI) 和综合歧视改进 (IDI) 评估预测性能;使用PROBAST评估偏差风险.
主要成果:
- 无论是BNP还是NT-proBNP,都始终改善了死亡率预测.
- 研究报告说,歧视有所改善,但缺乏对显著差异的正式统计测试.
- 由于数据异质性和缺乏有关性能变化的信息,无法进行元分析;大多数研究都有高偏差风险.
结论:
- BNP和NT-proBNP显示出改善瑞士法郎死亡率预测的潜力.
- 不一致的研究和报告阻碍了对其增加的预后价值的全面理解.
- 标准化报告对于有意义地解释CHF中的生物标志物附加值研究至关重要.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
521
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
521
01:29Heart Failure II: Pathophysiology
685
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
01:22Heart Failure Drugs: Diuretics
768
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
768
01:30Heart Failure V: Medical Management
200
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
01:30Heart Failure VII: Nursing Interventions
397
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
397